NewcelX (NCEL) Total Non-Current Liabilities (2022 - 2025)
NewcelX (NCEL) posted quarterly Total Non-Current Liabilities of $4.2 million for Q4 2025, up 9.3% year-over-year from $3.8 million in Q4 2024, and up 9.3% quarter-over-quarter from $3.8 million in Q4 2024.
NewcelX (NCEL) Total Non-Current Liabilities (2022 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Total Non-Current Liabilities for 4 consecutive years, with $4.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 9.3% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $4.2 million (up 9.3% YoY), while the FY2025 annual figure was $4.2 million, up 9.3% from the prior year.
- Total Non-Current Liabilities grew to $4.2 million in Q4 2025 per NCEL's latest filing, from $3.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $4.2 million in Q4 2025 and bottomed at $5000.0 in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $1.4 million across 4 years, with a median of $323000.0 in 2022.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slumped 98.92% — and 2024, when it jumped 76660.0%.
- NewcelX's Total Non-Current Liabilities stood at $463000.0 in 2022, then plunged by 98.92% to $5000.0 in 2023, then surged by 76660.0% to $3.8 million in 2024, then advanced by 9.3% to $4.2 million in 2025.
- Business Quant data shows NCEL's Total Non-Current Liabilities at $4.2 million in Q4 2025, $3.8 million in Q4 2024, and $6000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 9.32 Bn |
| 10 | NewcelX | 12.65 Mn | 10.45 Mn | - | 4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.20 Mn |
| Dec 31, 2024 | 3.84 Mn |
| Jun 30, 2024 | 6,000.00 |
| Dec 31, 2023 | 5,000.00 |
| Jun 30, 2023 | 183,000.00 |
| Dec 31, 2022 | 463,000.00 |